BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22566223)

  • 1. Case study: contamination of heparin with oversulfated chondroitin sulfate.
    Chess EK; Bairstow S; Donovan S; Havel K; Hu P; Johnson RJ; Lee S; McKee J; Miller R; Moore E; Nordhaus M; Ray J; Szabo C; Wielgos T
    Handb Exp Pharmacol; 2012; (207):99-125. PubMed ID: 22566223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure elucidation and biological activity of the oversulfated chondroitin sulfate contaminant in Baxter heparin.
    McKee J; Bairstow S; Szabo C; Ray J; Wielgos T; Hu P; Chess E; Nordhaus M; Hai T; Campbell J; Donovan S; Viseux N; Riedel N; Cammack J; Johnson R
    J Clin Pharmacol; 2010 Oct; 50(10):1159-70. PubMed ID: 20147614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008.
    McMahon AW; Pratt RG; Hammad TA; Kozlowski S; Zhou E; Lu S; Kulick CG; Mallick T; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2010 Sep; 19(9):921-33. PubMed ID: 20661880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products.
    Bairstow S; McKee J; Nordhaus M; Johnson R
    Anal Biochem; 2009 May; 388(2):317-21. PubMed ID: 19289093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of oversulfated chondroitin sulfate and dermatan sulfate impurities in heparin by capillary electrophoresis.
    Somsen GW; Tak YH; ToraƱo JS; Jongen PM; de Jong GJ
    J Chromatogr A; 2009 May; 1216(18):4107-12. PubMed ID: 19272607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Source-induced fragmentation of heparin, heparan, and galactosaminoglycans and application.
    Hu P; Fang L; Chess EK
    Anal Chem; 2009 Mar; 81(6):2332-43. PubMed ID: 19228018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate.
    Clark M; Hoppensteadt D; Walenga J; Myers L; Cunanan J; Jeske W; Adiguzel C; Iqbal O; Fareed J
    Int Angiol; 2008 Oct; 27(5):370-6. PubMed ID: 18974698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin identification test and purity test for OSCS in heparin sodium and heparin calcium by weak anion-exchange high-performance liquid chromatography.
    Hashii N; Kawasaki N; Itoh S; Qin Y; Fujita N; Hattori T; Miyata K; Bando A; Sekimoto Y; Hama T; Kashimura M; Tatsumi M; Mabuchi K; Namekawa H; Sakai T; Hirose M; Dobashi S; Shimahashi H; Koyama S; Herr SO; Kawai K; Yoden H; Yamaguchi T
    Biologicals; 2010 Sep; 38(5):539-43. PubMed ID: 20452241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oversulfated chondroitin sulfate interaction with heparin-binding proteins: new insights into adverse reactions from contaminated heparins.
    Li B; Suwan J; Martin JG; Zhang F; Zhang Z; Hoppensteadt D; Clark M; Fareed J; Linhardt RJ
    Biochem Pharmacol; 2009 Aug; 78(3):292-300. PubMed ID: 19389385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oversulfated chondroitin sulfate and OSCS-contaminated heparin cause dose- and route-dependent hemodynamic effects in the rat.
    Corbier A; Le Berre N; Rampe D; Meng H; Lorenz M; Vicat P; Potdevin S; Doubovetzky M
    Toxicol Sci; 2011 Jun; 121(2):417-27. PubMed ID: 21436127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oversulfated chondroitin sulfate is not the sole contaminant in heparin.
    Pan J; Qian Y; Zhou X; Pazandak A; Frazier SB; Weiser P; Lu H; Zhang L
    Nat Biotechnol; 2010 Mar; 28(3):203-7; author reply 207-11. PubMed ID: 20212477
    [No Abstract]   [Full Text] [Related]  

  • 12. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events.
    Guerrini M; Beccati D; Shriver Z; Naggi A; Viswanathan K; Bisio A; Capila I; Lansing JC; Guglieri S; Fraser B; Al-Hakim A; Gunay NS; Zhang Z; Robinson L; Buhse L; Nasr M; Woodcock J; Langer R; Venkataraman G; Linhardt RJ; Casu B; Torri G; Sasisekharan R
    Nat Biotechnol; 2008 Jun; 26(6):669-75. PubMed ID: 18437154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Taq polymerase as a method for screening heparin for oversulfated contaminants.
    Tami C; Puig M; Reepmeyer JC; Ye H; D'Avignon DA; Buhse L; Verthelyi D
    Biomaterials; 2008 Dec; 29(36):4808-14. PubMed ID: 18801571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative capillary electrophoresis determination of oversulfated chondroitin sulfate as a contaminant in heparin preparations.
    Volpi N; Maccari F; Linhardt RJ
    Anal Biochem; 2009 May; 388(1):140-5. PubMed ID: 19232311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of oversulfated chondroitin sulfate in low molecular weight and unfractioned heparins diffusion ordered nuclear magnetic resonance spectroscopy method.
    Sitkowski J; Bednarek E; Bocian W; Kozerski L
    J Med Chem; 2008 Dec; 51(24):7663-5. PubMed ID: 19055319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of heparin sodium by SAX/HPLC for contaminants and impurities.
    Trehy ML; Reepmeyer JC; Kolinski RE; Westenberger BJ; Buhse LF
    J Pharm Biomed Anal; 2009 Apr; 49(3):670-3. PubMed ID: 19167854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outbreak of adverse reactions associated with contaminated heparin.
    Blossom DB; Kallen AJ; Patel PR; Elward A; Robinson L; Gao G; Langer R; Perkins KM; Jaeger JL; Kurkjian KM; Jones M; Schillie SF; Shehab N; Ketterer D; Venkataraman G; Kishimoto TK; Shriver Z; McMahon AW; Austen KF; Kozlowski S; Srinivasan A; Turabelidze G; Gould CV; Arduino MJ; Sasisekharan R
    N Engl J Med; 2008 Dec; 359(25):2674-84. PubMed ID: 19052120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining (1)H NMR spectroscopy and chemometrics to identify heparin samples that may possess dermatan sulfate (DS) impurities or oversulfated chondroitin sulfate (OSCS) contaminants.
    Zang Q; Keire DA; Wood RD; Buhse LF; Moore CM; Nasr M; Al-Hakim A; Trehy ML; Welsh WJ
    J Pharm Biomed Anal; 2011 Apr; 54(5):1020-9. PubMed ID: 21215547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A nanosensor for ultrasensitive detection of oversulfated chondroitin sulfate contaminant in heparin.
    Kalita M; Balivada S; Swarup VP; Mencio C; Raman K; Desai UR; Troyer D; Kuberan B
    J Am Chem Soc; 2014 Jan; 136(2):554-7. PubMed ID: 24127748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of impurities in heparin by capillary electrophoresis using high molarity phosphate buffers.
    Wielgos T; Havel K; Ivanova N; Weinberger R
    J Pharm Biomed Anal; 2009 Feb; 49(2):319-26. PubMed ID: 19155153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.